Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Monitoring Compliance of Subject Activities – V 2.0

Posted on By

BA-BE Studies: SOP for Monitoring Compliance of Subject Activities – V 2.0

Standard Operating Procedure for Monitoring Compliance of Subject Activities in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/097/2025
Supersedes SOP/BA-BE/097/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a uniform procedure for monitoring and ensuring compliance of subjects with protocol-defined activities and restrictions during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies to maintain data integrity and subject safety.

2. Scope

This SOP applies to all clinical personnel responsible for supervising volunteer activities including dietary restrictions, dosing adherence, movement limitations, and post-dose behavioral protocols at the study site.

3. Responsibilities

  • Volunteer Coordinator: Informs subjects of activity-related rules and documents acknowledgment.
  • Clinical Research Coordinator (CRC): Ensures compliance is monitored and deviations are recorded.
  • Study Nurse: Observes activities and reports any deviation from permitted conduct.
  • Principal Investigator (PI): Reviews all deviations and determines the impact on study participation.
See also  BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period - V 2.0

4. Accountability

The Principal Investigator is accountable for ensuring that subject compliance is monitored and maintained as per protocol and regulatory requirements throughout the clinical phase.

5. Procedure

5.1 Informing Subjects of Compliance Requirements

  1. At check-in, provide subjects with verbal and written instructions regarding:
    • Restricted diet and water intake timings
    • Permissible physical activity levels
    • Usage of medications, smoking, alcohol, or caffeine
    • Mandatory rest or observation periods
  2. Record acknowledgment on Annexure-1: Subject Compliance Agreement Form.

5.2 Monitoring Subject Behavior

  1. Assign clinical staff to observe volunteers continuously during the confinement period.
  2. Log all activities including:
    • Time and quantity of meals and water
    • Movement within the unit
    • Sleep and wake times
  3. Record observations on Annexure-2: Subject Activity Monitoring Sheet.
See also  BA-BE Studies: SOP for Informed Consent Process Execution - V 2.0

5.3 Managing Non-Compliance

  1. Examples of non-compliance include:
    • Eating unauthorized food
    • Leaving the designated area without permission
    • Using restricted substances
  2. Document the incident in Annexure-3: Non-Compliance Log and report to PI.
  3. The PI decides on continuation, withdrawal, or additional monitoring of the subject.

5.4 Re-Training and Documentation

  1. In case of repeated or critical deviations:
    • Provide retraining to the subject
    • Document the corrective action taken

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • PI: Principal Investigator

7. Documents

  1. Subject Compliance Agreement Form – Annexure-1
  2. Subject Activity Monitoring Sheet – Annexure-2
  3. Non-Compliance Log – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Study Protocol
  • Schedule Y – Drugs and Cosmetics Rules
See also  BA-BE Studies: SOP for Maintaining Privacy and Confidentiality of Volunteers - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Subject Compliance Agreement Form

Subject ID Date Informed By Signature of Subject
VOL-097 17/04/2025 Sunita Reddy Rajesh Kumar

Annexure-2: Subject Activity Monitoring Sheet

Time Activity Observed Remarks Observer
09:00 AM Resting in bed Compliant Vinay Pawar

Annexure-3: Non-Compliance Log

Date Subject ID Description Action Taken Notified To
17/04/2025 VOL-097 Left designated zone Verbal warning PI

Revision History:

Revision Date Revision No. Details Reason Approved By
15/01/2022 1.0 Initial Release New Compliance SOP QA Head
17/04/2025 2.0 Updated observation and retraining procedures Audit Recommendation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Preparation and Use of Working Standards in AMD – V 2.0
Next Post: API Manufacturing: SOP for Equipment Line Clearance Before Drying – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version